Neurogesx, Inc. (NGSX) Cash Flow Statement

Click line-items for a historical chart and %

Operating activities
Net loss	-20.46M
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	242K
Amortization of debt issuance costs and accretion of debt discount	1.6M
Amortization of investment premiums	229K
Stock-based compensation	1.71M
Gain on disposal of property and equipment	114K
Changes in operating assets and liabilities:
Restricted cash
Trade receivables	720K
Receivable from collaboration partner
Prepaid expenses and other current assets	-53K
Inventories	601K
Accounts payable	-941K
Accrued compensation
Accrued research and development	2K
Accrued license fees
Accrued interest payable on long term obligations	5.28M
Deferred product revenue, net	-711K
Deferred collaboration revenue	-5.44M
Deferred rent
Other accrued expenses	-1.18M
Net cash used in operating activities	-18.99M
Investing activities
Purchases of short-term investments	-15.95M
Proceeds from maturities of short-term investments	31.33M
Proceeds from sales of short-term investments	0
Purchases of property and equipment	-73K
Net cash provided by (used in) investing activities	15.31M
Financing activities
Repayment of notes payable
Payments of long term obligation issuance costs	0
Proceeds from issuance of long term obligations	0
Proceeds from issuance of common stock	2.92M
Net cash provided by financing activities	2.48M
Net decrease in cash and cash equivalents	-1.19M
Cash and cash equivalents, beginning of period	9.15M
Cash and cash equivalents, end of period	7.96M
Supplemental cash flow information
Cash paid for interest

Entities mentioned with NGSX